Carcinoembryonic Antigen Global Market Report 2025
상품코드:1825645
리서치사:The Business Research Company
발행일:On Demand Report
페이지 정보:영문 250 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
암배아항원(CEA) 시장 규모는 향후 몇 년 동안 급성장할 것으로 예측됩니다. 2029년 연평균 성장률(CAGR)은 12.6%로 22억 1,000만 달러에 달할 것으로 예측됩니다. 예측 기간의 성장은 조기 발견 및 예방에 대한 집중, 암 검진 프로그램 확대, 개인 맞춤형 의료에 대한 환자 수요, 저침습적 진단 기법에 대한 수요 증가에 기인합니다. 예측 기간의 주요 동향으로는 개인 맞춤형 의료 도입 확대, 진단 플랫폼의 기술 발전, 인공지능 및 빅데이터와의 통합, 공동 연구 및 파트너십, 규제 당국의 승인 및 상환 정책 등을 들 수 있습니다.
향후 5년간 12.6%의 성장률 전망은 지난번 예측보다 0.8% 소폭 하락한 수치입니다. 이 감소는 주로 미국과 다른 국가 간의 관세의 영향에 기인합니다. 무역 마찰은 벨기에와 네덜란드에서 개발된 자동화된 암배아항원(CEA)(CEA) 측정 시약과 효소 결합 면역 흡착 측정(ELISA) 키트의 가격을 급등시켜 암 재발 발견을 지연시켜 미국의 암 모니터링에 지장을 초래할 수 있습니다. 또한, 상호 관세와 무역 긴장과 제한 증가로 인한 세계 경제와 무역에 대한 악영향으로 인해 그 영향은 더욱 광범위하게 나타날 것으로 보입니다.
암배아항원(CEA) 시장의 성장은 암 발병률 증가가 견인할 것으로 예측됩니다. 비정상적인 세포의 증식과 확산을 특징으로 하는 암은 생활습관 선택, 환경오염, 유전적 요인, 고령화 등 다양한 요인으로 인해 증가 추세에 있습니다. 암배아항원(CEA)(CEA)은 암 관리에서 종양 마커로서 질병의 진행과 치료 효과를 모니터링하는 데 도움을 주고 있습니다. 예를 들어, 세계보건기구(WHO)는 2024년 2월, 2050년에 새로 발생할 것으로 예상되는 암 환자 수는 약 3,500만 명으로 2022년 추정치인 2,000만 명보다 77% 증가할 것으로 보고했습니다. 이러한 암 환자의 급증은 암배아항원(CEA) 시장의 성장에 중요한 촉진제 역할을 하고 있습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 동향과 전략
제4장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세, 그리고 코로나재난과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오
제5장 세계의 성장 분석과 전략 분석 프레임워크
세계의 암배아항원(CEA) : PESTEL 분석(정치, 사회, 기술, 환경, 법적 요인, 촉진요인과 억제요인)
최종 이용 산업 분석
세계의 암배아항원(CEA) 시장 : 성장률 분석
세계의 암배아항원(CEA) 시장 실적 : 규모와 성장, 2019-2024
세계의 암배아항원(CEA) 시장 예측 : 규모와 성장, 2024-2029, 2034F
세계의 암배아항원(CEA) : 전체 시장 규모(TAM)
제6장 시장 세분화
세계의 암배아항원(CEA) 시장 테스트 유형별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
분자 검사
혈청학적 검사
세계의 암배아항원(CEA) 시장 : 성별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
남성
여성
세계의 암배아항원(CEA) 시장 : 용도별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
소화기암
대장암
췌장암
유방암
폐암
갑상선암
난소암
기타 용도
세계의 암배아항원(CEA) 시장 : 최종사용자별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
병원
진단센터
암센터
연구 및 학술기관
세계의 암배아항원(CEA) 시장 : 세분화 분자 검사 유형, 분석과 예측, 2019-2024, 2024-2029F, 2034F
중합효소 연쇄반응(PCR)
역전사진 PCR(RT-PCR)
차세대 시퀀싱(NGS)
Fluorescence In Situ Hybridization(FISH)
유전자 발현 프로파일링
세계의 암배아항원(CEA) 시장 : 세분화 혈청학적 검사(유형별), 분석과 예측, 2019-2024, 2024-2029F, 2034F
효소 면역측정법(ELISA)
화학 발광 면역측정법(CLIA)
방사면역측정(RIA)
면역조직화학(IHC)
측면 흐름 분석
제7장 지역별/국가별 분석
세계의 암배아항원(CEA) 시장 : 지역별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
세계의 암배아항원(CEA) 시장 : 국가별, 분석과 예측, 2019-2024, 2024-2029F, 2034F
제8장 아시아태평양 시장
제9장 중국 시장
제10장 인도 시장
제11장 일본 시장
제12장 호주 시장
제13장 인도네시아 시장
제14장 한국 시장
제15장 서유럽 시장
제16장 영국 시장
제17장 독일 시장
제18장 프랑스 시장
제19장 이탈리아 시장
제20장 스페인 시장
제21장 동유럽 시장
제22장 러시아 시장
제23장 북미 시장
제24장 미국 시장
제25장 캐나다 시장
제26장 남미 시장
제27장 브라질 시장
제28장 중동 시장
제29장 아프리카 시장
제30장 경쟁 구도와 기업 개요
암배아항원(CEA) 시장 : 경쟁 구도
암배아항원(CEA) 시장 : 기업 개요
F. Hoffmann-La Roche Ltd. : 개요, 제품 및 서비스, 전략 및 재무 분석
Thermo Fisher Scientific Inc. : 개요, 제품 및 서비스, 전략 및 재무 분석
Abbott Laboratories : 개요, 제품 및 서비스, 전략 및 재무 분석
Merck KGaA : 개요, 제품 및 서비스, 전략 및 재무 분석
Siemens Healthineers : 개요, 제품 및 서비스, 전략 및 재무 분석
제31장 기타 주요 기업 및 혁신 기업
Laboratory Corporation of America Holdings
Quest Diagnostics
Agilent Technologies, Inc.
Beckman Coulter Inc.
bioMerieux SA
Quidel Corporation
Ortho Clinical Diagnostics
Abcam plc
RayBiotech Inc.
Creative Diagnostics
Lee Biosolutions Inc.
Hytest Ltd.
Prospec-Tany Technogene Ltd
Boster Biological Technology
Metropolis Healthcare
제32장 세계 시장 경쟁 벤치마킹과 대시보드
제33장 주요 인수합병(M&A)
제34장 최근 시장 동향
제35장 시장 잠재력이 높은 국가, 부문, 전략
암배아항원(CEA) 시장(2029년) : 새로운 기회를 제공하는 국가
암배아항원(CEA) 시장(2029년) : 새로운 기회를 제공하는 부문
암배아항원(CEA) 시장(2029년) : 성장 전략
시장 동향에 근거한 전략
경쟁 전략
제36장 부록
LSH
영문 목차
영문목차
Carcinoembryonic antigen (CEA) is a glycoprotein primarily involved in cell adhesion, commonly found in embryonic tissues and various carcinomas. In clinical practice, CEA serves as a tumor marker crucial for diagnosing, monitoring, and managing cancer, especially colorectal cancer. It aids in evaluating the efficacy of cancer treatments and is used for post-treatment monitoring to detect signs of cancer recurrence.
The main types of carcinoembryonic antigen tests include molecular tests and serology tests. Molecular tests for CEA involve analyzing genetic material, such as DNA or RNA, to measure CEA levels. These tests can be applied across genders, including males and females, and are used in various cancer types such as gastrointestinal cancer, colorectal cancer, pancreatic cancer, breast cancer, lung cancer, thyroid cancer, ovarian cancer, among others. End-users of these tests include hospitals, diagnostic centers, cancer centers, and research institutes.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The carcinoembryonic antigen market research report is one of a series of new reports from The Business Research Company that provides carcinoembryonic antigen market statistics, including the carcinoembryonic antigen industry global market size, regional shares, competitors with the carcinoembryonic antigen market share, detailed carcinoembryonic antigen market segments, market trends, and opportunities, and any further data you may need to thrive in the carcinoembryonic antigen industry. These carcinoembryonic antigen market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The carcinoembryonic antigen market size has grown rapidly in recent years. It will grow from $1.22 billion in 2024 to $1.38 billion in 2025 at a compound annual growth rate (CAGR) of 13.5%. The growth in the historic period can be attributed to cancer prevalence globally, aging population, awareness campaigns, healthcare infrastructure development, and reimbursement policies.
The carcinoembryonic antigen market size is expected to see rapid growth in the next few years. It will grow to $2.21 billion in 2029 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to focus on early detection and prevention, expansion of cancer screening programs, patient demand for personalized medicine, growing demand for minimally invasive diagnostic procedures. Major trends in the forecast period include increased adoption of personalized medicine, technological advancements in diagnostic platforms, integration with artificial intelligence and big data, collaborations and partnerships, and regulatory approvals and reimbursement policies.
The forecast of 12.6% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology monitoring by inflating prices of automated Carcinoembryonic antigen(CEA) assay reagents and Enzyme-linked immunosorbent assay(ELISA) kits developed in Belgium and the Netherlands, resulting in delayed cancer recurrence detection. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The growth of the carcinoembryonic antigen market is expected to be driven by an increase in cancer incidence. Cancer, characterized by abnormal cell growth and spread, is on the rise due to various factors such as lifestyle choices, environmental pollution, genetic factors, and an aging population. Carcinoembryonic antigen (CEA) serves as a tumor marker in cancer management, aiding in monitoring disease progression and treatment efficacy. For instance, the World Health Organization (WHO) reported in February 2024 that the predicted number of new cancer cases in 2050 is around 35 million, marking a 77% increase from the estimated 20 million cases in 2022. This surge in cancer cases is a key driver for the carcinoembryonic antigen market's growth.
Major companies in the carcinoembryonic antigen market are increasingly focusing on developing tumor marker tests to improve the testing process and enhance diagnostic capabilities. Tumor marker tests are diagnostic procedures designed to detect specific substances in the body that may indicate the presence of cancer. For example, in July 2023, Roche Diagnostics, a Switzerland-based healthcare diagnostics company, introduced the Elecsys HCV Duo, a dual antigen and antibody diagnostic test that supports India's efforts in combating hepatitis C. This innovative test enables the simultaneous detection of hepatitis C virus (HCV) antigen and antibody status from a single sample, significantly improving early diagnosis of active infections and facilitating timely treatment. The Elecsys HCV Duo helps fill critical diagnostic gaps, especially in high-transmission populations, thereby enhancing the overall effectiveness of hepatitis screening initiatives.
In December 2023, Danaher Corporation acquired Abcam Limited to enhance its capabilities and expand its market presence in life sciences and diagnostics. Abcam Limited, a producer and distributor of protein research tools including recombinant human carcinoembryonic antigen CEA protein, contributes to Danaher's offerings in the field.
Major companies operating in the carcinoembryonic antigen market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Merck KGaA, Siemens Healthineers, Laboratory Corporation of America Holdings, Quest Diagnostics, Agilient Technologies, Inc., Beckman Coulter Inc., bioMerieux SA, Quidel Corporation, Ortho Clinical Diagnostics, Abcam plc, RayBiotech Inc., Creative Diagnostics, Lee Biosolutions Inc., Hytest Ltd., Prospec-Tany Technogene Ltd, Boster Biological Technology, Metropolis Healthcare
North America was the largest region in the carcinoembryonic antigen market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the carcinoembryonic antigen market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the carcinoembryonic antigen market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The carcinoembryonic antigen market consists of sales of diagnostic kits or assays. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Carcinoembryonic Antigen Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on carcinoembryonic antigen market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for carcinoembryonic antigen ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The carcinoembryonic antigen market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:1) By Test Type: Molecular Tests; Serology Tests
2) By Gender: Male; Female
3) By Application: Gastrointestinal Cancer; Colorectal Cancer; Pancreatic Cancer; Breast Cancer; Lung Cancer; Thyroid Cancer; Ovarian Cancer; Other Applications
4) By End User: Hospitals; Diagnostic Centers; Cancer Centers; Research And Academic Institutes
3. Carcinoembryonic Antigen market Trends And Strategies
4. Carcinoembryonic Antigen market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Carcinoembryonic Antigen Growth Analysis And Strategic Analysis Framework
5.1. Global Carcinoembryonic Antigen PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Carcinoembryonic Antigen market Growth Rate Analysis
5.4. Global Carcinoembryonic Antigen Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Carcinoembryonic Antigen Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Carcinoembryonic Antigen Total Addressable Market (TAM)
6. Carcinoembryonic Antigen market Segmentation
6.1. Global Carcinoembryonic Antigen market, Segmentation By Test Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Molecular Tests
Serology Tests
6.2. Global Carcinoembryonic Antigen market, Segmentation By Gender, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Male
Female
6.3. Global Carcinoembryonic Antigen market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Gastrointestinal Cancer
Colorectal Cancer
Pancreatic Cancer
Breast Cancer
Lung Cancer
Thyroid Cancer
Ovarian Cancer
Other Applications
6.4. Global Carcinoembryonic Antigen market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Diagnostic Centers
Cancer Centers
Research And Academic Institutes
6.5. Global Carcinoembryonic Antigen Market, Sub-Segmentation Of Molecular Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Polymerase Chain Reaction (PCR)
Reverse Transcription PCR (RT-PCR)
Next-Generation Sequencing (NGS)
Fluorescence In Situ Hybridization (FISH)
Gene Expression Profiling
6.6. Global Carcinoembryonic Antigen Market, Sub-Segmentation Of Serology Tests, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Enzyme-Linked Immunosorbent Assay (ELISA)
Chemiluminescent Immunoassay (CLIA)
Radioimmunoassay (RIA)
Immunohistochemistry (IHC)
Lateral Flow Assays
7. Carcinoembryonic Antigen market Regional And Country Analysis
7.1. Global Carcinoembryonic Antigen market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Carcinoembryonic Antigen market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
